Pathway Therapeutics Ltd

pathway therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific pi3-kinase (pi3k) inhibitors for oncology and inflammation. the company’s lead product, pwt33597, is a balanced dual pi3k alpha/mtor inhibitor for which an ind application has been filed. pathway therapeutics is also developing pi3k delta inhibitors for hematological malignancies and inflammatory diseases and irreversible pi3k inhibitors. pathway therapeutics will target its development programs towards specific populations of patients most likely to respond to pi3k pathway inhibition. this focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activiti